Ronald M Witteles, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Witteles’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A76510 · Current
Licensed to practise in California · since 2001 · expires 2027-04-30 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$92,507
Medicare paid this office $92,507 for 402 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 111 | $17,685 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $13,112 | $103 |
| Critical care, first 30-74 minutes | 22 | $11,303 | $179 |
| Return visit (30+ min) | 120 | $9,628 | $77 |
| New patient visit (60+ min) | 54 | $8,486 | $157 |
See all 16 services
| Long return visit (40+ min) | 111 | $17,685 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $13,112 | $103 |
| Critical care, first 30-74 minutes | 22 | $11,303 | $179 |
| Return visit (30+ min) | 120 | $9,628 | $77 |
| New patient visit (60+ min) | 54 | $8,486 | $157 |
| Long return visit (40+ min) | 36 | $7,150 | $159 |
| Return visit (30+ min) | 49 | $5,929 | $116 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 57 | $3,737 | $29 |
| Critical care, each additional 30 minutes | 13 | $2,790 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,564 | $142 |
| Hospital discharge day management, 30 minutes or less | 27 | $2,029 | $72 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $1,451 | $23 |
| Programming of multiple lead implantable defibrillator system | 23 | $1,428 | $49 |
| Programming of dual lead implantable defibrillator system | 15 | $833 | $46 |
| Programming of dual lead pacemaker system | 13 | $531 | $31 |
| Programming of multiple lead pacemaker system | 11 | $409 | $37 |
Who their Medicare patients are
402 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 15% · Women 32% · Also on Medicaid 17% · Health risk score 2.31. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 75% · Atrial fibrillation 54% · Coronary heart disease 46% · Chronic kidney disease 45% · Diabetes 33% · Cancer 20% · Depression 15% · COPD 14% · Stroke 9% · Dementia 8%.
The office billed $444,122, Medicare allowed $121,225 and paid $92,507; for 1,003 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 402 | 1,003 | 76 | 2.31 | $444,122 | $92,507 |
| 2023 | 433 | 1,161 | 75 | 2.28 | $573,624 | $116,645 |
| 2022 | 412 | 1,298 | 75 | 2.42 | $792,376 | $137,664 |
| 2021 | 410 | 1,276 | 74 | 2.47 | $666,043 | $127,311 |
| 2020 | 408 | 1,337 | 74 | 2.61 | $673,736 | $131,171 |
| 2019 | 420 | 1,183 | 74 | 2.54 | $402,629 | $110,658 |
| 2018 | 378 | 1,246 | 73 | 2.75 | $525,124 | $120,957 |
| 2017 | 367 | 1,269 | 72 | 2.68 | $605,588 | $126,839 |
| 2016 | 362 | 1,199 | 72 | 2.60 | $595,709 | $123,054 |
| 2015 | 318 | 1,037 | 72 | 2.48 | $447,138 | $100,404 |
| 2014 | 321 | 1,227 | 72 | 2.30 | $486,836 | $117,392 |
| 2013 | 389 | 1,128 | 71 | 2.14 | $389,138 | $92,046 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $24,683 | $109 |
| Critical care, first 30-74 minutes | 38 | $22,721 | $191 |
| Long return visit (40+ min) | 121 | $21,676 | $129 |
| Return visit (30+ min) | 176 | $15,137 | $78 |
| New patient visit (60+ min) | 52 | $8,526 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $5,773 | $156 |
| Hospital discharge day management, 30 minutes or less | 41 | $3,163 | $75 |
| Critical care, each additional 30 minutes | 15 | $2,894 | $96 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 51 | $2,595 | $32 |
| Programming of dual lead implantable defibrillator system | 32 | $1,730 | $48 |
| Programming of multiple lead implantable defibrillator system | 28 | $1,708 | $52 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 21 | $937 | $27 |
| Programming of dual lead pacemaker system | 17 | $657 | $35 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 18 | $431 | $22 |
2022: 15 services
| Critical care, first 30-74 minutes | 42 | $44,696 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $19,387 | $94 |
| Long return visit (40+ min) | 112 | $18,774 | $121 |
| Return visit (30+ min) | 171 | $15,581 | $79 |
| New patient visit (60+ min) | 69 | $11,197 | $162 |
| Critical care, each additional 30 minutes | 26 | $7,405 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,224 | $178 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 53 | $2,954 | $32 |
| Hospital discharge day management, 30 minutes or less | 33 | $2,281 | $65 |
| Programming of multiple lead implantable defibrillator system | 22 | $1,661 | $54 |
| Programming of dual lead implantable defibrillator system | 23 | $1,530 | $53 |
| Programming of dual lead pacemaker system | 17 | $635 | $33 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 24 | $622 | $25 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 17 | $585 | $34 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $471 | $20 |
2021: 14 services
| Critical care, first 30-74 minutes | 49 | $29,179 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $24,223 | $95 |
| Return visit (30+ min) | 200 | $19,634 | $80 |
| Long return visit (40+ min) | 75 | $12,237 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $10,362 | $185 |
| New patient visit (60+ min) | 48 | $8,338 | $174 |
| Critical care, each additional 30 minutes | 26 | $5,806 | $100 |
| Hospital discharge day management, 30 minutes or less | 60 | $4,280 | $68 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 51 | $3,118 | $32 |
| Programming of dual lead implantable defibrillator system | 30 | $1,781 | $46 |
| Programming of multiple lead implantable defibrillator system | 21 | $1,534 | $51 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $534 | $25 |
| Programming of dual lead pacemaker system | 13 | $504 | $36 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 12 | $420 | $35 |
2020: 15 services
| Critical care, first 30-74 minutes | 45 | $34,464 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $22,853 | $96 |
| Return visit (30+ min) | 178 | $15,141 | $67 |
| Long return visit (40+ min) | 112 | $13,748 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,713 | $183 |
| Critical care, each additional 30 minutes | 29 | $9,333 | $101 |
| New patient visit (60+ min) | 29 | $4,562 | $157 |
| Hospital discharge day management, 30 minutes or less | 58 | $4,067 | $67 |
| Return visit (30+ min) | 45 | $3,281 | $73 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 51 | $3,132 | $34 |
| Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes | 11 | $2,220 | $202 |
| Programming of multiple lead implantable defibrillator system | 24 | $1,628 | $51 |
| Programming of dual lead implantable defibrillator system | 23 | $1,451 | $48 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 23 | $522 | $23 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 12 | $467 | $36 |
2019: 13 services
| Long return visit (40+ min) | 160 | $21,639 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $18,933 | $94 |
| Critical care, first 30-74 minutes | 21 | $14,988 | $197 |
| Return visit (30+ min) | 149 | $11,956 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $10,278 | $184 |
| New patient visit (60+ min) | 63 | $8,964 | $142 |
| Hospital discharge day management, 30 minutes or less | 56 | $3,782 | $68 |
| Programming of dual lead implantable defibrillator system | 40 | $3,273 | $50 |
| Critical care, each additional 30 minutes | 16 | $3,077 | $99 |
| Programming of multiple lead implantable defibrillator system | 36 | $3,008 | $52 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 38 | $2,375 | $40 |
| New patient visit (45+ min) | 17 | $1,749 | $103 |
| Programming of dual lead pacemaker system | 17 | $675 | $32 |
2018: 15 services
| Critical care, first 30-74 minutes | 41 | $25,999 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $23,661 | $93 |
| Long return visit (40+ min) | 125 | $19,223 | $94 |
| Return visit (30+ min) | 133 | $10,998 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,915 | $182 |
| New patient visit (60+ min) | 41 | $6,171 | $151 |
| Critical care, each additional 30 minutes | 22 | $5,003 | $98 |
| Hospital discharge day management, 30 minutes or less | 67 | $4,881 | $67 |
| Programming of dual lead implantable defibrillator system | 30 | $2,639 | $52 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 31 | $2,413 | $48 |
| New patient visit (45+ min) | 18 | $2,002 | $111 |
| Programming of multiple lead implantable defibrillator system | 28 | $1,781 | $46 |
| Programming of dual lead pacemaker system | 14 | $542 | $34 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 11 | $408 | $31 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $270 | $25 |
2017: 15 services
| Critical care, first 30-74 minutes | 43 | $33,107 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $22,435 | $93 |
| Long return visit (40+ min) | 108 | $15,621 | $95 |
| Return visit (30+ min) | 152 | $12,901 | $66 |
| Critical care, each additional 30 minutes | 26 | $8,559 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,717 | $179 |
| New patient visit (60+ min) | 46 | $6,670 | $145 |
| Hospital discharge day management, 30 minutes or less | 54 | $3,776 | $66 |
| New patient visit (45+ min) | 26 | $2,888 | $111 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 36 | $2,828 | $52 |
| Programming of dual lead implantable defibrillator system | 33 | $2,477 | $52 |
| Programming of multiple lead implantable defibrillator system | 17 | $1,607 | $55 |
| Programming of dual lead pacemaker system | 15 | $698 | $33 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $514 | $24 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 12 | $418 | $35 |
2016: 14 services
| Critical care, first 30-74 minutes | 47 | $32,557 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $30,146 | $92 |
| Long return visit (40+ min) | 101 | $14,574 | $96 |
| Return visit (30+ min) | 120 | $10,393 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $9,374 | $180 |
| Critical care, each additional 30 minutes | 23 | $5,301 | $98 |
| New patient visit (60+ min) | 31 | $4,592 | $148 |
| Hospital discharge day management, 30 minutes or less | 62 | $4,076 | $66 |
| New patient visit (45+ min) | 34 | $3,922 | $115 |
| Programming of dual lead implantable defibrillator system | 27 | $1,744 | $48 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 15 | $1,167 | $51 |
| Programming of multiple lead implantable defibrillator system | 18 | $1,135 | $57 |
| Programming of dual lead pacemaker system | 12 | $488 | $33 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $265 | $24 |
2015: 13 services
| Critical care, first 30-74 minutes | 44 | $22,704 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $21,470 | $91 |
| Long return visit (40+ min) | 78 | $12,288 | $95 |
| Return visit (30+ min) | 121 | $9,599 | $62 |
| Critical care, each additional 30 minutes | 18 | $7,863 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,337 | $181 |
| New patient visit (60+ min) | 28 | $4,186 | $149 |
| Hospital discharge day management, 30 minutes or less | 57 | $3,755 | $66 |
| New patient visit (45+ min) | 31 | $3,364 | $109 |
| Programming of multiple lead implantable defibrillator system | 21 | $1,643 | $53 |
| Programming of dual lead implantable defibrillator system | 21 | $1,500 | $50 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 19 | $1,458 | $54 |
| Programming of dual lead pacemaker system | 14 | $829 | $35 |
2014: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $32,769 | $92 |
| Critical care, first 30-74 minutes | 39 | $21,697 | $195 |
| Return visit (30+ min) | 141 | $11,994 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $11,962 | $179 |
| Long return visit (40+ min) | 75 | $11,107 | $96 |
| Critical care, each additional 30 minutes | 18 | $7,823 | $98 |
| Hospital discharge day management, 30 minutes or less | 66 | $4,584 | $65 |
| New patient visit (60+ min) | 24 | $3,590 | $150 |
| New patient visit (45+ min) | 28 | $3,104 | $111 |
| Programming of dual lead implantable defibrillator system | 22 | $2,064 | $49 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 21 | $1,656 | $52 |
| Programming of multiple lead implantable defibrillator system | 19 | $1,168 | $45 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 14 | $741 | $41 |
| Programming of dual lead pacemaker system | 11 | $452 | $27 |
2013: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $21,291 | $90 |
| Critical care, first 30-74 minutes | 34 | $20,046 | $191 |
| Return visit (30+ min) | 146 | $13,763 | $63 |
| Long return visit (40+ min) | 71 | $7,740 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,472 | $175 |
| Critical care, each additional 30 minutes | 17 | $5,161 | $96 |
| New patient visit (60+ min) | 24 | $3,491 | $145 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 21 | $2,769 | $53 |
| New patient visit (45+ min) | 22 | $2,481 | $113 |
| Hospital discharge day management, 30 minutes or less | 35 | $2,301 | $64 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 26 | $1,128 | $38 |
| Programming of dual lead implantable defibrillator system | 17 | $1,097 | $48 |
| Programming of multiple lead implantable defibrillator system | 13 | $868 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 110 | $851 | $7 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 12 | $257 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $220 | $18 |
Medicaid work
$867 in 2024
Medicaid paid $867 for 32 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $867 |
| 2024 | 32 | 1 | 12 | $867 |
| 2023 | 12 | 1 | 12 | $306 |
| 2022 | 130 | 2 | 13 | $5,967 |
| 2021 | 193 | 1 | 14 | $5,886 |
| 2020 | 39 | 2 | 12 | $2,168 |
| 2019 | 77 | 1 | 13 | $2,246 |
See the largest Medicaid services in earlier years
2023
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 12 | $306 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 117 | $5,599 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 13 | $368 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 193 | $5,886 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $1,982 |
| Return visit (30+ min) | 12 | $186 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 77 | $2,246 |
Drugs they prescribed that Part D paid
$17,921,531
Pharmacies billed $17,921,531 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,519) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,886 generic and fewer than 11 brand-name prescriptions · $17,921,531 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 621 | $14,562,044 | $23,449 |
| Vyndaqel | 95 | $2,145,241 | $22,581 |
| Jardiance | 339 | $464,787 | $1,371 |
| Eliquis | 250 | $341,777 | $1,367 |
| Entresto | 169 | $262,583 | $1,554 |
See all 29 drugs
| Vyndamax | 621 | $14,562,044 | $23,449 |
| Vyndaqel | 95 | $2,145,241 | $22,581 |
| Jardiance | 339 | $464,787 | $1,371 |
| Eliquis | 250 | $341,777 | $1,367 |
| Entresto | 169 | $262,583 | $1,554 |
| Farxiga | 56 | $61,333 | $1,095 |
| Xarelto | 34 | $35,726 | $1,051 |
| Eplerenone | 74 | $9,744 | $132 |
| Spironolactone | 313 | $3,405 | $11 |
| Metoprolol | 183 | $3,148 | $17 |
| Carvedilol | 249 | $2,873 | $12 |
| Methotrexate | 42 | $2,786 | $66 |
| Ezetimibe | 40 | $2,345 | $59 |
| Bumetanide | 36 | $2,035 | $57 |
| Furosemide | 249 | $1,813 | $7 |
| Atorvastatin | 120 | $1,742 | $15 |
| Rosuvastatin | 70 | $1,141 | $16 |
| Torsemide | 17 | $729 | $43 |
| Amlodipine Besylate | 98 | $658 | $7 |
| Losartan | 94 | $647 | $7 |
| Levothyroxine | 27 | $491 | $18 |
| Potassium Chloride | 13 | $421 | $32 |
| Hydralazine | 18 | $331 | $18 |
| Clopidogrel | 29 | $327 | $11 |
| Digoxin | 19 | $309 | $16 |
| Amiodarone | 19 | $279 | $15 |
| Hydrochlorothiazide | 27 | $233 | $9 |
| Isosorbide Mononitrate Er | 14 | $226 | $16 |
| Lisinopril | 50 | $143 | $3 |
Year by year
| 2024 | 3,519 | 326 | 0% (0) | None | $17,921,531 |
| 2023 | 3,356 | 308 | 0% (0) | 42% | $13,300,432 |
| 2022 | 3,226 | 307 | 0% (0) | None | $10,462,468 |
| 2021 | 2,786 | 276 | 0% (0) | None | $8,630,309 |
| 2020 | 2,947 | 296 | 0% (0) | None | $7,885,020 |
| 2019 | 2,724 | 311 | 0% (0) | None | $2,618,839 |
| 2018 | 2,748 | 278 | 0% (0) | None | $290,754 |
| 2017 | 2,296 | 259 | None | 23% | $197,483 |
| 2016 | 2,136 | 236 | None | None | $155,514 |
| 2015 | 2,267 | 222 | 0% (0) | None | $127,959 |
| 2014 | 2,484 | 221 | None | None | $109,014 |
| 2013 | 2,079 | 185 | None | None | $92,916 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Vyndamax | 500 | $10,983,005 | $21,966 |
| Vyndaqel | 53 | $1,216,452 | $22,952 |
| Eliquis | 271 | $342,003 | $1,262 |
| Entresto | 215 | $319,694 | $1,487 |
| Jardiance | 241 | $291,880 | $1,211 |
| Farxiga | 35 | $43,550 | $1,244 |
| Xarelto | 33 | $39,819 | $1,207 |
| Eplerenone | 72 | $10,927 | $152 |
| Bumetanide | 44 | $5,643 | $128 |
| Spironolactone | 333 | $4,871 | $15 |
| Carvedilol | 270 | $4,426 | $16 |
| Metoprolol | 148 | $3,266 | $22 |
| Rosuvastatin | 60 | $3,020 | $50 |
| Atorvastatin | 138 | $2,899 | $21 |
| Methotrexate | 35 | $2,661 | $76 |
| Furosemide | 251 | $2,657 | $11 |
| Ezetimibe | 26 | $1,560 | $60 |
| Losartan | 91 | $1,041 | $11 |
| Amlodipine Besylate | 88 | $862 | $10 |
| Amiodarone | 23 | $851 | $37 |
| Hydralazine | 21 | $634 | $30 |
| Digoxin | 21 | $524 | $25 |
| Torsemide | 22 | $515 | $23 |
| Lisinopril | 70 | $474 | $7 |
| Isosorbide Mononitrate Er | 15 | $415 | $28 |
| Potassium Chloride | 14 | $395 | $28 |
| Levothyroxine | 26 | $383 | $15 |
| Clopidogrel | 20 | $354 | $18 |
| Hydrochlorothiazide | 35 | $342 | $10 |
| Metoprolol | 13 | $262 | $20 |
| Donepezil | 12 | $243 | $20 |
| Pravastatin | 11 | $167 | $15 |
| Diltiazem 24hr Er (Xr) | 12 | $151 | $13 |
| Nitroglycerin | 15 | $116 | $8 |
2022: 33 drugs
| Vyndamax | 403 | $8,458,597 | $20,989 |
| Vyndaqel | 54 | $1,150,212 | $21,300 |
| Entresto | 261 | $299,766 | $1,149 |
| Eliquis | 272 | $269,605 | $991 |
| Jardiance | 140 | $135,088 | $965 |
| Xarelto | 35 | $44,572 | $1,273 |
| Farxiga | 39 | $30,699 | $787 |
| Eplerenone | 77 | $20,344 | $264 |
| Spironolactone | 332 | $4,174 | $13 |
| Bumetanide | 31 | $4,081 | $132 |
| Rosuvastatin | 43 | $3,737 | $87 |
| Carvedilol | 235 | $2,948 | $13 |
| Methotrexate | 43 | $2,711 | $63 |
| Furosemide | 248 | $2,695 | $11 |
| Metoprolol | 135 | $2,620 | $19 |
| Amiodarone | 25 | $2,576 | $103 |
| Midodrine | 17 | $2,138 | $126 |
| Atorvastatin | 127 | $2,083 | $16 |
| Ezetimibe | 31 | $1,932 | $62 |
| Digoxin | 35 | $1,085 | $31 |
| Losartan | 108 | $1,038 | $10 |
| Amlodipine Besylate | 103 | $831 | $8 |
| Isosorbide Mononitrate Er | 30 | $815 | $27 |
| Potassium Chloride | 19 | $666 | $35 |
| Hydralazine | 18 | $577 | $32 |
| Torsemide | 25 | $557 | $22 |
| Lisinopril | 74 | $479 | $6 |
| Levothyroxine | 21 | $444 | $21 |
| Hydrochlorothiazide | 29 | $385 | $13 |
| Pantoprazole | 13 | $232 | $18 |
| Donepezil | 12 | $216 | $18 |
| Clopidogrel | 14 | $215 | $15 |
| Metoprolol | 18 | $157 | $9 |
2021: 31 drugs
| Vyndamax | 333 | $6,681,328 | $20,064 |
| Vyndaqel | 68 | $1,364,352 | $20,064 |
| Eliquis | 242 | $226,478 | $936 |
| Entresto | 150 | $173,422 | $1,156 |
| Jardiance | 63 | $55,880 | $887 |
| Xarelto | 46 | $49,267 | $1,071 |
| Farxiga | 20 | $14,076 | $704 |
| Eplerenone | 58 | $12,831 | $221 |
| Spironolactone | 311 | $4,490 | $14 |
| Methotrexate | 34 | $3,711 | $109 |
| Carvedilol | 241 | $3,524 | $15 |
| Metoprolol | 147 | $3,052 | $21 |
| Bumetanide | 35 | $2,920 | $83 |
| Furosemide | 240 | $2,411 | $10 |
| Midodrine | 24 | $2,111 | $88 |
| Atorvastatin | 132 | $1,979 | $15 |
| Rosuvastatin | 39 | $1,678 | $43 |
| Digoxin | 39 | $1,330 | $34 |
| Amiodarone | 19 | $1,292 | $68 |
| Losartan | 112 | $1,131 | $10 |
| Lisinopril | 66 | $912 | $14 |
| Ezetimibe | 16 | $749 | $47 |
| Torsemide | 11 | $704 | $64 |
| Amlodipine Besylate | 64 | $612 | $10 |
| Levothyroxine | 18 | $558 | $31 |
| Hydralazine | 20 | $454 | $23 |
| Isosorbide Mononitrate Er | 20 | $410 | $20 |
| Hydrochlorothiazide | 27 | $313 | $12 |
| Potassium Chloride | 19 | $274 | $14 |
| Metoprolol | 14 | $166 | $12 |
| Prednisone | 12 | $99 | $8 |
2020: 27 drugs
| Vyndamax | 217 | $4,313,393 | $19,877 |
| Vyndaqel | 153 | $3,136,304 | $20,499 |
| Eliquis | 216 | $176,412 | $817 |
| Entresto | 143 | $139,963 | $979 |
| Xarelto | 50 | $39,782 | $796 |
| Eplerenone | 52 | $9,266 | $178 |
| Spironolactone | 328 | $4,138 | $13 |
| Metoprolol | 141 | $3,647 | $26 |
| Bumetanide | 38 | $3,014 | $79 |
| Amiodarone | 39 | $2,923 | $75 |
| Carvedilol | 297 | $2,907 | $10 |
| Furosemide | 302 | $2,791 | $9 |
| Midodrine | 35 | $2,613 | $75 |
| Methotrexate | 34 | $2,598 | $76 |
| Atorvastatin | 149 | $2,313 | $16 |
| Rosuvastatin | 24 | $1,866 | $78 |
| Digoxin | 45 | $1,600 | $36 |
| Losartan | 126 | $1,492 | $12 |
| Isosorbide Mononitrate Er | 36 | $993 | $28 |
| Lisinopril | 68 | $619 | $9 |
| Hydralazine | 40 | $597 | $15 |
| Levothyroxine | 27 | $587 | $22 |
| Amlodipine Besylate | 68 | $479 | $7 |
| Metoprolol | 39 | $457 | $12 |
| Potassium Chloride | 18 | $451 | $25 |
| Hydrochlorothiazide | 38 | $415 | $11 |
| Pantoprazole | 20 | $294 | $15 |
2019: 34 drugs
| Vyndaqel | 100 | $2,022,403 | $20,224 |
| Vyndamax | 11 | $213,735 | $19,430 |
| Eliquis | 178 | $128,836 | $724 |
| Entresto | 150 | $102,645 | $684 |
| Xarelto | 65 | $34,329 | $528 |
| Eplerenone | 97 | $29,073 | $300 |
| Bumetanide | 59 | $7,261 | $123 |
| Amiodarone | 52 | $4,160 | $80 |
| Metoprolol | 136 | $3,922 | $29 |
| Carvedilol | 283 | $3,794 | $13 |
| Spironolactone | 283 | $3,497 | $12 |
| Furosemide | 238 | $2,658 | $11 |
| Midodrine | 20 | $2,472 | $124 |
| Methotrexate | 23 | $2,450 | $107 |
| Atorvastatin | 117 | $2,001 | $17 |
| Digoxin | 48 | $1,746 | $36 |
| Losartan | 133 | $1,331 | $10 |
| Hydralazine | 46 | $1,331 | $29 |
| Isosorbide Mononitrate Er | 38 | $1,201 | $32 |
| Rosuvastatin | 18 | $1,182 | $66 |
| Torsemide | 32 | $1,160 | $36 |
| Lisinopril | 64 | $1,048 | $16 |
| Diflunisal | 14 | $968 | $69 |
| Potassium Chloride | 25 | $968 | $39 |
| Digox | 13 | $685 | $53 |
| Amlodipine Besylate | 57 | $583 | $10 |
| Metoprolol | 36 | $499 | $14 |
| Hydrochlorothiazide | 44 | $423 | $10 |
| Levothyroxine | 24 | $380 | $16 |
| Tamsulosin | 18 | $348 | $19 |
| Gabapentin | 13 | $278 | $21 |
| Warfarin | 12 | $172 | $14 |
| Clopidogrel | 11 | $104 | $9 |
| Omeprazole | 12 | $83 | $7 |
2018: 34 drugs
| Eliquis | 143 | $94,747 | $663 |
| Entresto | 117 | $70,556 | $603 |
| Xarelto | 78 | $40,916 | $525 |
| Eplerenone | 79 | $16,123 | $204 |
| Carvedilol | 344 | $3,868 | $11 |
| Spironolactone | 346 | $3,857 | $11 |
| Amiodarone | 57 | $3,494 | $61 |
| Bumetanide | 51 | $3,365 | $66 |
| Atorvastatin | 136 | $2,682 | $20 |
| Metoprolol | 104 | $2,547 | $24 |
| Furosemide | 282 | $2,446 | $9 |
| Digoxin | 55 | $2,260 | $41 |
| Ezetimibe | 11 | $1,908 | $173 |
| Diflunisal | 21 | $1,870 | $89 |
| Isosorbide Mononitrate Er | 54 | $1,770 | $33 |
| Midodrine | 17 | $1,493 | $88 |
| Valsartan | 23 | $1,376 | $60 |
| Digox | 21 | $1,218 | $58 |
| Losartan | 138 | $1,202 | $9 |
| Hydralazine | 60 | $1,155 | $19 |
| Potassium Chloride | 24 | $1,002 | $42 |
| Lisinopril | 66 | $989 | $15 |
| Amlodipine Besylate | 82 | $773 | $9 |
| Hydrochlorothiazide | 65 | $543 | $8 |
| Rosuvastatin | 12 | $412 | $34 |
| Tamsulosin | 12 | $351 | $29 |
| Metoprolol | 29 | $350 | $12 |
| Pantoprazole | 19 | $316 | $17 |
| Warfarin | 14 | $287 | $20 |
| Allopurinol | 11 | $247 | $22 |
| Clopidogrel | 21 | $245 | $12 |
| Simvastatin | 12 | $130 | $11 |
| Gabapentin | 11 | $128 | $12 |
| Omeprazole | 14 | $75 | $5 |
2017: 34 drugs
| Xarelto | 66 | $38,589 | $585 |
| Eliquis | 72 | $36,780 | $511 |
| Entresto | 52 | $31,204 | $600 |
| Eplerenone | 58 | $17,316 | $299 |
| Brilinta | 15 | $4,986 | $332 |
| Spironolactone | 342 | $3,702 | $11 |
| Bumetanide | 33 | $3,497 | $106 |
| Amiodarone | 36 | $3,184 | $88 |
| Midodrine | 37 | $2,826 | $76 |
| Carvedilol | 276 | $2,253 | $8 |
| Metoprolol | 70 | $2,158 | $31 |
| Digoxin | 37 | $2,086 | $56 |
| Furosemide | 288 | $1,800 | $6 |
| Valsartan | 18 | $1,445 | $80 |
| Atorvastatin | 72 | $1,352 | $19 |
| Diflunisal | 13 | $1,289 | $99 |
| Losartan | 122 | $1,080 | $9 |
| Isosorbide Mononitrate Er | 42 | $1,073 | $26 |
| Digox | 17 | $1,020 | $60 |
| Hydralazine | 42 | $771 | $18 |
| Amlodipine Besylate | 79 | $709 | $9 |
| Torsemide | 21 | $563 | $27 |
| Levothyroxine | 25 | $542 | $22 |
| Lisinopril | 72 | $506 | $7 |
| Clopidogrel | 31 | $439 | $14 |
| Warfarin | 18 | $361 | $20 |
| Simvastatin | 27 | $325 | $12 |
| Metoprolol | 29 | $325 | $11 |
| Hydrochlorothiazide | 32 | $323 | $10 |
| Pravastatin | 15 | $285 | $19 |
| Diltiazem 24hr Er | 12 | $277 | $23 |
| Potassium Chloride | 15 | $241 | $16 |
| Pantoprazole | 14 | $162 | $12 |
| Niacor | 12 | $123 | $10 |
2016: 37 drugs
| Xarelto | 66 | $37,326 | $566 |
| Eliquis | 35 | $15,945 | $456 |
| Eplerenone | 45 | $10,733 | $239 |
| Pradaxa | 20 | $9,502 | $475 |
| Entresto | 18 | $8,005 | $445 |
| Zetia | 15 | $6,058 | $404 |
| Spironolactone | 271 | $3,130 | $12 |
| Amiodarone | 42 | $3,073 | $73 |
| Colchicine | 14 | $3,021 | $216 |
| Metoprolol | 78 | $2,780 | $36 |
| Valsartan | 32 | $2,647 | $83 |
| Carvedilol | 222 | $2,228 | $10 |
| Furosemide | 269 | $1,640 | $6 |
| Bumetanide | 26 | $1,620 | $62 |
| Digoxin | 43 | $1,613 | $38 |
| Potassium Chloride | 28 | $1,099 | $39 |
| Atorvastatin | 46 | $1,065 | $23 |
| Hydralazine | 59 | $958 | $16 |
| Isosorbide Mononitrate Er | 49 | $914 | $19 |
| Midodrine | 21 | $797 | $38 |
| Losartan | 91 | $743 | $8 |
| Lisinopril | 62 | $664 | $11 |
| Digox | 15 | $615 | $41 |
| Levothyroxine | 26 | $571 | $22 |
| Diltiazem 24hr Cd | 14 | $540 | $39 |
| Amlodipine Besylate | 61 | $469 | $8 |
| Torsemide | 13 | $412 | $32 |
| Warfarin | 26 | $377 | $15 |
| Methotrexate | 12 | $375 | $31 |
| Metoprolol | 38 | $340 | $9 |
| Clopidogrel | 34 | $339 | $10 |
| Simvastatin | 33 | $289 | $9 |
| Benazepril | 18 | $158 | $9 |
| Niacor | 12 | $125 | $10 |
| Pantoprazole | 14 | $121 | $9 |
| Venlafaxine Hcl Er | 11 | $108 | $10 |
| Hydrochlorothiazide | 19 | $89 | $5 |
2015: 36 drugs
| Xarelto | 82 | $35,203 | $429 |
| Pradaxa | 27 | $10,720 | $397 |
| Eliquis | 19 | $8,252 | $434 |
| Eplerenone | 39 | $7,818 | $200 |
| Crestor | 23 | $6,011 | $261 |
| Midodrine | 22 | $4,558 | $207 |
| Colchicine | 14 | $3,255 | $233 |
| Spironolactone | 287 | $2,520 | $9 |
| Metoprolol | 80 | $2,392 | $30 |
| Amiodarone | 70 | $2,271 | $32 |
| Carvedilol | 259 | $2,219 | $9 |
| Furosemide | 257 | $1,703 | $7 |
| Digoxin | 35 | $1,596 | $46 |
| Methotrexate | 18 | $1,575 | $87 |
| Atorvastatin | 61 | $1,554 | $25 |
| Valsartan | 25 | $1,511 | $60 |
| Hydralazine | 82 | $1,416 | $17 |
| Isosorbide Mononitrate Er | 75 | $1,161 | $15 |
| Potassium Chloride | 41 | $992 | $24 |
| Levothyroxine | 38 | $767 | $20 |
| Losartan | 90 | $556 | $6 |
| Diltiazem 24hr Cd | 14 | $492 | $35 |
| Lisinopril | 76 | $474 | $6 |
| Digox | 14 | $458 | $33 |
| Clopidogrel | 36 | $393 | $11 |
| Metoprolol | 51 | $357 | $7 |
| Warfarin | 44 | $322 | $7 |
| Simvastatin | 33 | $313 | $9 |
| Amlodipine Besylate | 39 | $309 | $8 |
| Tamsulosin | 13 | $296 | $23 |
| Ramipril | 14 | $222 | $16 |
| Hydrochlorothiazide | 29 | $212 | $7 |
| Prednisone | 12 | $176 | $15 |
| Allopurinol | 13 | $152 | $12 |
| Metformin | 28 | $133 | $5 |
| Escitalopram | 12 | $100 | $8 |
2014: 42 drugs
| Xarelto | 68 | $26,919 | $396 |
| Crestor | 27 | $8,615 | $319 |
| Pradaxa | 24 | $7,145 | $298 |
| Eliquis | 20 | $5,932 | $297 |
| Diovan | 18 | $4,201 | $233 |
| Methotrexate | 33 | $3,694 | $112 |
| Metoprolol | 94 | $3,415 | $36 |
| Amiodarone | 57 | $3,313 | $58 |
| Colcrys | 12 | $2,916 | $243 |
| Eplerenone | 26 | $2,859 | $110 |
| Carvedilol | 263 | $2,824 | $11 |
| Spironolactone | 233 | $2,323 | $10 |
| Hydralazine | 111 | $2,272 | $20 |
| Digox | 35 | $1,910 | $55 |
| Furosemide | 264 | $1,606 | $6 |
| Isosorbide Mononitrate Er | 108 | $1,530 | $14 |
| Atorvastatin | 64 | $1,401 | $22 |
| Digoxin | 24 | $1,266 | $53 |
| Midodrine | 17 | $1,264 | $74 |
| Losartan | 85 | $1,008 | $12 |
| Lisinopril | 125 | $797 | $6 |
| Amlodipine Besylate | 78 | $728 | $9 |
| Potassium Chloride | 22 | $634 | $29 |
| Tamsulosin | 21 | $563 | $27 |
| Levothyroxine | 36 | $559 | $16 |
| Prednisone | 27 | $491 | $18 |
| Clopidogrel | 22 | $422 | $19 |
| Simvastatin | 42 | $409 | $10 |
| Warfarin | 43 | $384 | $9 |
| Ramipril | 12 | $357 | $30 |
| Metformin | 35 | $347 | $10 |
| Metoprolol | 49 | $336 | $7 |
| Diltiazem 24hr Cd | 12 | $263 | $22 |
| Hydrochlorothiazide | 38 | $263 | $7 |
| Enalapril Maleate | 11 | $178 | $16 |
| Benazepril | 19 | $163 | $9 |
| Omeprazole | 16 | $157 | $10 |
| Zolpidem | 12 | $156 | $13 |
| Allopurinol | 16 | $108 | $7 |
| Gabapentin | 13 | $108 | $8 |
| Sulfamethoxazole-Trimethoprim | 16 | $71 | $4 |
| Folic Acid | 13 | $37 | $3 |
2013: 35 drugs
| Xarelto | 55 | $15,421 | $280 |
| Diovan | 62 | $12,675 | $204 |
| Pradaxa | 36 | $10,450 | $290 |
| Eplerenone | 32 | $5,943 | $186 |
| Crestor | 14 | $4,756 | $340 |
| Carvedilol | 262 | $3,608 | $14 |
| Metoprolol | 95 | $2,991 | $31 |
| Spironolactone | 188 | $2,472 | $13 |
| Colcrys | 12 | $2,432 | $203 |
| Hydralazine | 91 | $2,392 | $26 |
| Atorvastatin | 45 | $1,835 | $41 |
| Isosorbide Mononitrate Er | 89 | $1,424 | $16 |
| Furosemide | 191 | $1,214 | $6 |
| Amlodipine Besylate | 106 | $989 | $9 |
| Losartan | 56 | $901 | $16 |
| Lisinopril | 118 | $788 | $7 |
| Clopidogrel | 28 | $697 | $25 |
| Amiodarone | 43 | $663 | $15 |
| Simvastatin | 63 | $613 | $10 |
| Isosorbide Dinitrate | 12 | $581 | $48 |
| Digox | 53 | $518 | $10 |
| Hydrochlorothiazide | 50 | $473 | $9 |
| Midodrine | 14 | $413 | $29 |
| Enalapril Maleate | 30 | $378 | $13 |
| Metoprolol | 39 | $333 | $9 |
| Warfarin | 20 | $315 | $16 |
| Pantoprazole | 12 | $303 | $25 |
| Ramipril | 16 | $266 | $17 |
| Tamsulosin | 19 | $262 | $14 |
| Benazepril | 28 | $218 | $8 |
| Levothyroxine | 13 | $141 | $11 |
| Pravastatin | 12 | $133 | $11 |
| Allopurinol | 16 | $119 | $7 |
| Digoxin | 11 | $112 | $10 |
| Metformin | 13 | $90 | $7 |
Money from drug and device companies
$39,578 in 2025
| 2025 | 5 | 19 | $37,322 | $39,578 |
| 2024 | 4 | 37 | $48,924 | $64,859 |
| 2023 | 6 | 19 | $33,062 | $47,173 |
| 2022 | 5 | 23 | $23,571 | $59,581 |
| 2021 | 4 | 6 | $14,793 | $14,793 |
| 2020 | 2 | 2 | $6,000 | $6,000 |
| 2019 | 4 | 19 | $16,945 | $18,606 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Vyndaqel | $13,849 | 6 payments
|
| Alnylam Pharmaceuticals | Onpattro | $11,207 | 7 payments
|
| BridgeBio Pharma | Attruby | $10,175 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Wainua | $2,737 | 2 payments
|
| AstraZeneca AB | None | $1,611 | 1 payment
|
See all 19 published payments
| BridgeBio Pharma | Meals · 2025-12-16 | Attruby | $146 |
| Pfizer | Consulting · 2025-11-24 | None | $2,800 |
| Pfizer | Paid to speak or teach · 2025-11-10 | Vyndaqel | $186 |
| Pfizer | Consulting · 2025-11-10 | Vyndaqel | $5,600 |
| Pfizer | Consulting · 2025-11-10 | Vyndaqel | $2,800 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-10-01 | Wainua | $2,685 |
| BridgeBio Pharma | Meals · 2025-10-01 | Attruby | $264 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-28 | Wainua | $52 |
| Alnylam Pharmaceuticals | Meals · 2025-09-26 | None | $132 |
| Alnylam Pharmaceuticals | Travel · 2025-09-26 | Amvuttra | $734 |
| Alnylam Pharmaceuticals | Travel · 2025-09-26 | Amvuttra | $621 |
| Alnylam Pharmaceuticals | Travel · 2025-09-26 | Amvuttra | $308 |
| Pfizer | Paid to speak or teach · 2025-08-25 | Vyndaqel | $1,063 |
| AstraZeneca AB | Consulting · 2025-07-10 | None | $1,611 |
| BridgeBio Pharma | Consulting · 2025-05-27 | Attruby | $9,765 |
| Pfizer | Consulting · 2025-04-17 | Vyndaqel | $1,400 |
| Alnylam Pharmaceuticals | Paid to speak or teach · 2025-03-29 | None | $4,125 |
| Alnylam Pharmaceuticals | Consulting · 2025-03-13 | None | $2,820 |
| Alnylam Pharmaceuticals | Consulting · 2025-01-16 | Onpattro | $2,468 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $64,859
| Pfizer | Vyndaqel | $45,311 | 18 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $10,117 | 16 payments
|
| Alexion Pharmaceuticals | None | $7,820 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $1,611 | 1 payment
|
2023: $47,173
| Novo Nordisk AS | None | $21,141 | 6 payments
|
| Alnylam Pharmaceuticals | Onpattro | $12,851 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Wainua | $4,961 | 3 payments
|
| Pfizer | Vyndaqel | $4,316 | 4 payments
|
| Alexion Pharmaceuticals | None | $3,680 | 1 payment
|
| Pfizer Corporation Hong Kong | Vyndamax | $224 | 1 payment
|
2022: $59,581
| Pfizer | Vyndaqel | $25,545 | 10 payments
|
| Novo Nordisk AS | None | $24,373 | 5 payments
|
| Alnylam Pharmaceuticals | None | $4,613 | 3 payments
|
| Alexion Pharmaceuticals | None | $3,645 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $1,405 | 4 payments
|
2021: $14,793
| Akcea Therapeutics | None | $5,300 | 2 payments
|
| Regeneron Pharmaceuticals | None | $5,265 | 2 payments
|
| Alnylam Pharmaceuticals | None | $2,460 | 1 payment
|
| Janssen Scientific Affairs | Darzalex | $1,768 | 1 payment
|
2020: $6,000
| Pfizer | Vyndaqel | $3,500 | 1 payment
|
| Pfizer International | Vyndaqel | $2,500 | 1 payment
|
2019: $18,606
| Alnylam Pharmaceuticals | Onpattro | $11,330 | 11 payments
|
| Pfizer | Vyndaqel | $7,030 | 6 payments
|
| Medtronic Vascular | Reveal Linq | $153 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $93 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2024 | Their institution | $850,188 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2021 | Their institution | $615,954 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2025 | Their institution | $411,471 |
| Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2023 | Their institution | $346,238 |
| Ionis Pharmaceuticals, Inc. · A Phase 3 Global Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy and Safety of Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025 | Their institution | $304,267 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2023 | Their institution | $166,833 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2022 | Their institution | $158,902 |
| PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2019 | Their institution | $158,664 |
| PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2020 | Their institution | $147,664 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2022 | Their institution | $133,542 |
| Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2020 | Their institution | $121,225 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2022 | Their institution | $120,144 |
| Alnylam Pharmaceuticals Inc. · An Open-Label Extension Study To Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2025 | Their institution | $97,623 |
| Ionis Pharmaceuticals, Inc. · An Openlabel Extension Study To Assess the Longterm Safety of Eplontersen Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025 | Their institution | $86,165 |
| Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2024 | Their institution | $36,455 |
| Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2021 | Their institution | $27,202 |
| Alexion Pharmaceuticals, Inc. · A Phase 3,Radomized,Double-Blind,Placebo-Controlled,Multicenter Study To Evaluate the Efficacy and Safety of Amyloid Depleter Alxn2220 in Adult Participants Wiith Transthyretin Amyloid Cardiomyopathy Attr Cm · 2025 | Their institution | $18,302 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2023 | Their institution | $11,897 |
| PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2025 | This clinician | $7,480 |
| PFIZER INC. · Tafamidis Clinical Publication Program · 2020 | This clinician | $6,890 |
| Genentech, Inc. · T Dm1 High Risk Ebc Pts With Residual Inv Disease · 2019 | This clinician | $6,800 |
| PFIZER INC. · Tafamidis Clinical Publication Program · 2022 | This clinician | $6,030 |
| PFIZER INC. · Tafamidis Clinical Publication Program · 2021 | This clinician | $5,740 |
| PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2023 | This clinician | $5,090 |
| PFIZER INC. · Vyndaqel Clinical Publication Program · 2024 | This clinician | $4,470 |
| Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2025 | Their institution | $4,310 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2024 | Their institution | $4,000 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2025 | Their institution | $4,000 |
| PFIZER INC. · Vyndamax Clinical Publication Program · 2023 | This clinician | $3,200 |
| Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2022 | Their institution | $2,491 |
| PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2022 | This clinician | $1,560 |
| PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2024 | This clinician | $1,440 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285779389
- Licence
- CA A76510California A76510: Current · expires 2027-04-30
- Trained
- University of Chicago, Pritzker School of Medicine, 2000
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-20
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.